ロード中...
Bronchopleural fistula in squamous cell lung cancer following anlotinib treatment: A case report
Anlotinib is a multi-target tyrosine kinase inhibitor and has been approved for the treatment of patients with advanced non-small cell lung cancer. The most common adverse events of this treatment include hypertension, fatigue, thyroid-stimulating hormone elevation, hypertriglyceridemia, hand-foot s...
保存先:
| 出版年: | Mol Clin Oncol |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
D.A. Spandidos
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6870048/ https://ncbi.nlm.nih.gov/pubmed/31798876 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2019.1939 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|